GSK's TYKERB® Receives Accelerated Approval For First-line Combination Treatment Of Hormone Receptor Positive, HER2+/ErbB2+ Breast Cancer

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer...

Advertisement:

read more

http://digg.com/u1LkhB